The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | GCLLSG trial results to be presented at the 2016 ASH Annual Meeting
Barbara Eichhorst, MD of the University of Cologne, Cologne, Germany gives an overview of the GCLLSG trials in chronic lymphocytic leukemia (CLL), which will be presented at the 2016 ASH Annual Meeting. First, Dr Eichhorst discusses the CLLM1 study evaluating lenalidomide maintenance in patients with residual disease and an unfavourable genetic profile after chemoimmunotherapy (NCT01556776). Further, the safety run-in phase data regarding the efficacy of venetoclax plus obinutuzumab in frontline therapy of less fit patients has been submitted to the 2016 ASH Annual Meeting. Finally, efficacy data of the CLL2-BIG study has been submitted to ASH 2016, which includes bendamustine debulking treatment and then induction treatment based on ibrutinib plus obinutuzumab followed by maintenance treatment with ibrutinib and obinutuzumab three monthly (NCT02345863). Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
